(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of 85.01% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.25%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.49%.
Syndax Pharmaceuticals's revenue in 2025 is $78,180,000.On average, 3 Wall Street analysts forecast SNDX's revenue for 2025 to be $14,460,031,381, with the lowest SNDX revenue forecast at $11,775,592,535, and the highest SNDX revenue forecast at $16,727,888,182. On average, 3 Wall Street analysts forecast SNDX's revenue for 2026 to be $27,922,023,149, with the lowest SNDX revenue forecast at $18,684,169,868, and the highest SNDX revenue forecast at $36,172,690,691.
In 2027, SNDX is forecast to generate $42,902,609,802 in revenue, with the lowest revenue forecast at $39,228,142,536 and the highest revenue forecast at $48,312,663,303.